BJOG An International Journal of Obstetrics & Gynaecology · 1995 · 415 citations · 17 references
MedicineMaternal HealthObstetricsMaternal-fetal MedicineObstetric UltrasoundPrenatal DiagnosisCongenital DisordersFetal AnomaliesFetal Anomaly DetectionFetal BiometryFetal Growth AssessmentFetal ImagingCongenital Anomaly Detection By UltrasonographyFetal Chromosomal AbnormalitiesMaternal Age DistributionMaternal Age EffectsNuchal Translucency ScreeningTrisomy Screening
OBJECTIVE: To evaluate screening for chromosomal defects by a combination of fetal nuchal translucency thickness and maternal age. DESIGN: A prospective multicentre screening study where fetal nuchal translucency thickness was measured at 10 to 14 weeks of gestation. SUBJECTS: 20,804 women with singleton pregnancies screened at 10 to 14 weeks of gestation from 1 September 1992 to 28 October 1994. MAIN OUTCOME MEASURES: Trisomy 21 and other chromosomal defects identified by increased nuchal translucency thickness and by a combination of nuchal translucency thickness and maternal age. RESULTS: In normal fetuses nuchal translucency thickness increased significantly with crown-rump length. The nuchal translucency was above the 95th centile in 77% (66 of 86) of fetuses with trisomy 21 and in 78% (61 of 78) of those with other chromosomal defects. On the basis of the distribution of nuchal translucency measurements in normal fetuses and those with trisomy 21, a new method of screening is proposed which involves assessment of individual risk based on the combination of fetal nuchal translucency, crown-rump length and maternal age. The minimum risk was 1/100 in 4.9% of the normal pregnancies, in 80% of those with trisomy 21 and in 77% of those with other chromosomal defects. CONCLUSION: Screening for fetal trisomy 21 can be carried out effectively during the first trimester of pregnancy.
17
K. H. Nicolaides, G.B. Azar, Dominic Byrne et al. · BMJ · 1992 · 1.1K citations · Full text
Medicine, Genetics, Obstetrics +17
RANDOMISED CONTROLLED TRIAL OF GENETIC AMNIOCENTESIS IN 4606 LOW-RISK WOMEN
Ann Tabor, Mette Madsen, Erikb. Obel et al. · The Lancet · 1986 · 873 citations
Medicine, Genetics, Obstetrics +8
Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
N J Wald, Anne Kennard, J. W. Densem et al. · BMJ · 1992 · 294 citations · Full text